A method of analysis of a human tumor, the method comprising detecting in a biological sample from the human tumor or in a biological sample comprising human tumor nucleic acids an increased expression level: - of 4 to 8 genes selected from gene signature A1 consisting of the genes AQP1, ITGA1, L1CAM, NLGN3, S100A4, IL1RAP, COL4A1, THBS2, SLITRK6, CADM1, NRXN1, A2M, PRIMA1, GFRA2, MPZ, ADAMTS4, GFRA1, RSPO3, GFRA3, LAMC1, ANXA1, SYT11, MATN2, ATP1B2, ADGB, CNN3, COL1A1, TMEM176B, PLAT, PDGFB, SLC22A17, ITGA6, NGFR, VCAN, ATP1A2, IGF1, SEMA3B; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of neural drug tolerant tumor cells (NDTCs); and - of 4 to 8 genes selected from gene signature B1 consisting of the genes SLC7A8, DLX5, TRIM67, CD36, PAX3, IP6K3, UBXN10, KIAA1161, LSMEM1; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of hypometabolic tumor cells (HMTCs); and - of 4 to 8 genes selected from gene signature C1 consisting of the genes SLC24A5, PMEL, FABP7, SLC45A2, KIT, EDNRB, TRPM1, APOE, MLANA, MLPH, TYRP1, GPR143, TYR, RAB27A, SNAI2, MITF, DCT; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of pigmented tumor cells; and - of 4 to 8 genes selected from gene signature D1 consisting of VCAN, TNC, BCAT1, FOSL2, UNC5B, CCL2, COL1A1, SH2B3, MGP, VEGFA, LOX, FGF1, PDGFRB, IGFBP5, ERRFI1, PRDX1, TGFBI, IL13RA2, SOX4, NES, LOXL2, SPRY2, CDH13, LMO4, RGS5, RGS16, DLX1, SLIT2, GPC3, ADM, EDNRA, CYSLTR2, DDAH1, PLXDC1, VSNL1, COL1A2, DLC1, AXL, ANGPTL4, IGFBP6, COL3A1, FABP4, CDH2, PTGER4, NDNF, NR2F1, BGN, TGM2, TMSB4X, CYR61, WNT5A, TCF4; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of invasive tumor cells; and wherein increased expression level of a selected gene is determined compared to a reference expression level of that selected gene. - of 4 to 8 genes selected from gene signature A1 consisting of the genes AQP1, ITGA1, L1CAM, NLGN3, S100A4, IL1RAP, COL4A1, THBS2, SLITRK6, CADM1, NRXN1, A2M, PRIMA1, GFRA2, MPZ, ADAMTS4, GFRA1, RSPO3, GFRA3, LAMC1, ANXA1, SYT11, MATN2, ATP1B2, ADGB, CNN3, COL1A1, TMEM176B, PLAT, PDGFB, SLC22A17, ITGA6, NGFR, VCAN, ATP1A2, IGF1, SEMA3B; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of neural drug tolerant tumor cells (NDTCs); and - of 4 to 8 genes selected from gene signature B1 consisting of the genes SLC7A8, DLX5, TRIM67, CD36, PAX3, IP6K3, UBXN10, KIAA1161, LSMEM1; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of hypometabolic tumor cells (HMTCs); and - of 4 to 8 genes selected from gene signature C1 consisting of the genes SLC24A5, PMEL, FABP7, SLC45A2, KIT, EDNRB, TRPM1, APOE, MLANA, MLPH, TYRP1, GPR143, TYR, RAB27A, SNAI2, MITF, DCT; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of pigmented tumor cells; and - of 4 to 8 genes selected from gene signature D1 consisting of VCAN, TNC, BCAT1, FOSL2, UNC5B, CCL2, COL1A1, SH2B3, MGP, VEGFA, LOX, FGF1, PDGFRB, IGFBP5, ERRFI1, PRDX1, TGFBI, IL13RA2, SOX4, NES, LOXL2, SPRY2, CDH13, LMO4, RGS5, RGS16, DLX1, SLIT2, GPC3, ADM, EDNRA, CYSLTR2, DDAH1, PLXDC1, VSNL1, COL1A2, DLC1, AXL, ANGPTL4, IGFBP6, COL3A1, FABP4, CDH2, PTGER4, NDNF, NR2F1, BGN, TGM2, TMSB4X, CYR61, WNT5A, TCF4; and wherein detection of an increased expression level of the selected genes is indicating the emergence or presence of invasive tumor cells; and